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Objectives: Patients with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED,
APS-I) suffer from chronic candidosis caused mainly by Candida albicans, and repeated courses of azole antifun-
gals have led to the development of resistance in the APECED patient population in Finland. The aim of our study
was to addresswhether the patients are persistently colonizedwith the sameor genetically closely related strains,
whether epidemic strains are present and which molecular mechanisms account for azole resistance.
Methods: Sets of C. albicans (n¼19) isolates from nine APECED patients reported with decreased susceptibility to
fluconazole isolated up to 9 years apart were included. The strains were typed by multilocus sequence typing.
CDR1/2, MDR1 and ERG11 mRNA expression was analysed by northern blotting and Cdr1, Cdr2 and Mdr1 protein
expression by western blotting, and TAC1 and ERG11 genes were sequenced.
Results:All seven patientswithmultiple C. albicans isolates analysedwere persistently colonizedwith the sameor
a genetically closely related strain for a mean of 5 years. All patients were colonized with different strains and no
epidemic strains were found. The major molecular mechanisms behind the azole resistance were mutations in
TAC1 contributing to overexpression of CDR1 and CDR2. Six new TAC1 mutations were found, one of which
(N740S) is likely to be a gain-of-function mutation. Most isolates were found to have gained multiple TAC1 and
ERG11 point mutations.
Conclusions: Despite clinically successful treatment leading to relief of symptoms, colonization by C. albicans
strains is persistent within APECED patients. Microevolution and point mutations occur within strains, leading to
the development of azole-resistant isolates.
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Introduction
Autoimmune polyendocrine syndrome type I (APECED, APS-I) is
an autosomal recessive disease caused by loss-of-function
mutations of the autoimmune regulator gene (Aire) on chromo-
some 21 q22.3.1,2 Lack of expression of the Aire protein allows
autoreactive T cells to escape negative selection in the thymus.
This leads to an autoimmune reaction mainly against various
endocrine glands as well as to the development of high-titre
auto-antibodies against interferon-v and -a.2 Although the syn-
drome is rare, cases have been reported in several geographical
areas.3 It has a relatively high prevalence in Finland (1:25000).
The first symptom of the disease in early childhood is often a
superficial Candida infection of the oral mucosa.3 Most patients
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develop high titres of Candida-specific antibodies but fail to
respond to Candida antigens and develop chronic mucocuta-
neous candidosis (CMC).4–7 Consequently, patients receive
repeated courses of antifungals from childhood. In the Finnish
APECED population, liberal use of azole antifungals has resulted
in clinical and microbiological resistance to azoles of the coloniz-
ing Candida albicans strains.8–10 Emergence of cross-resistance
between the azoles that the patients had been treated with
and newer azole compounds that they had not been exposed
to has also been reported.10 In HIV patients, long-term use of
azoles has similarly been reported to cause loss of susceptibility
of C. albicans to fluconazole as well as the development of
azole cross-resistance.11 The resistance mechanisms operating
in C. albicans from APECED patients have not yet been
investigated.
Several mechanisms are known to result in azole resistance in
C. albicans. Azoles, including fluconazole, target lanosterol
14a-demethylase, which is a product of the ERG11 gene.12
Point mutations and upregulation of ERG11 can occur and have
been identified in resistant clinical isolates.12–14 The majority of
the point mutations associated with resistance alter the
binding of azoles to Erg11p.15 Another mechanism involved in
azole resistance is the failure to accumulate azoles in yeast
cells, which may be caused either by impaired drug import or
increased drug efflux.16 Multidrug efflux transporters of the ATP-
binding cassette (ABC) superfamily and of the major facilitator
(MF) class have a key role in this low-level azole accumulation.
CDR1 and CDR2, genes for ABC transporters, and MDR1, a gene
for MF transporters, have been shown to be upregulated in resist-
ant strains, leading to enhanced drug efflux.12,13,17 This in turn
leads to a reduced inhibition of their target encoded by the
ERG11 gene. MDR1 is often not detectable in azole-susceptible
strains, whereas the transcription of CDR1 may be detectable
also in azole-susceptible strains and is elevated in strains with
decreased susceptibility. Deletion of CDR1 and CDR2 results in
hypersusceptible isolates.13,18 CDR2 upregulation is usually com-
bined with CDR1 upregulation due to a mutual activator, the
transcriptional activator of CDR genes (TAC1).19 TAC1 is located
close to the mating-type locus (MTL), and previous studies
have shown a correlation between homozygosity (a/a or a/a)
at the MTL and azole resistance.14,20,21
It has been demonstrated that TAC1 mutations, so-called
gain-of-function (GOF) mutations, are associated with hyperac-
tivity of the encoded protein, which is itself responsible for
enhanced transcription of TAC1 target genes, including CDR1
and CDR2.19 It is therefore expected that isolates with high
CDR1 and CDR2 expression will exhibit GOF mutations. Mrr1p
has been shown to control MDR1 expression in C. albicans and
GOF mutations in the MRR1 gene result in upregulation of
MDR1.22
Using sets of multiple isolates, our study aimed firstly to
analyse whether APECED patients with persistent oral candidosis
were colonized with the same C. albicans strain over several
years or whether they had become re-infected with new
strains after antifungal treatment. Secondly, we asked whether
epidemic strains existed within the APECED population in
Finland. Thirdly, we analysed the molecular mechanisms
behind azole resistance in these isolates and looked for signs
of microvariation in the persisting C. albicans strains developing
resistance.
Patients and methods
C. albicans isolates
The 19 C. albicans isolates used in this study had been isolated from
1995 to 2007 from the oral cavities of nine APECED patients suffering
from CMC (1–3 isolates/patient). Patients with at least one isolate
with decreased susceptibility to fluconazole or signs of clinical resist-
ance were included. From these patients multiple isolates with various
susceptibilities over many years were selected when available. The
C. albicans isolates had been identified from patient samples using con-
ventional culture and identification methods at the Clinical Microbiology
Laboratory of Helsinki University Central Hospital. The identification of
C. albicans was based on colony morphology on CHROMagarw Candida
medium (CHROMagar, Paris, France) and a negative Bichro-Dubliw
latex co-agglutination test result for Candida dubliniensis (Fumouze
Diagnostics, Levallois Perret, France). The strains had been stored in
milk–glycerin at –708C.
Growth media
The C. albicans strains were subcultured in complete YEPD broth (1%
Bacto peptone; Difco Laboratories, Basel, Switzerland), 0.5% yeast
extract (Difco) and 2% glucose (Fluka, Buchs, Switzerland) and sub-
sequently on YEPD agar.
Susceptibility testing
The susceptibility profiles of the isolates to fluconazole and itraconazole
were re-analysed by Etest (AB Biodisk, Sweden) according to the manu-
facturer’s instructions and as described previously.23 Quality control for
susceptibility testing was performed using C. albicans strains ATCC
90028 and ATCC 24433 and Candida glabrata strain ATCC 90030.
Strain typing
Multilocus sequence typing (MLST) was used to type the C. albicans iso-
lates. Sequences of bases in the gene fragments from seven housekeep-
ing genes (AAT1a, ACC1, ADP1, MPI1b, SYA1, VPS13 and ZWF1b) were
determined and the isolates were tested by MLST as described earlier
using an ABI Prism 3700 genetic analyser (PE Applied Biosystems).24,25
In brief, isolation of genomic DNA was performed as described earlier
from an overnight culture.26 DNA polymerase Expand High Fidelity
(Roche, Basel) was used for the amplification of DNA by PCR. Sequences
of primers used are listed in Table 1. Sequence data were analysed for
polymorphisms using Contig Express software (Invitrogen, Basel).
Sequence data were entered into the MLST database (http://test1.mlst.
net) to provide a diploid sequence type (DST) for each strain. According
to sequence types, strains were analysed to determine clonal clusters
by the eBURST program and each strain was given a clonal cluster
number. Clonal clusters were defined as groups of isolates with six of
the seven genotype sequences being identical.27 The unweighted pair-
group method with arithmetic averages (UPGMA) was used to display
strains as a dendrogram.
Analysis of MTL status
The MTL type/status was determined by PCR by amplifying the MTLa and
MTLa genes as described previously.28 Sequences of primers used are
listed in Table 1. The MTL was assessed as heterozygous (a/a), homozy-
gous (a/a) or homozygous (a/a). The correlations between the MTL
type and MIC and between MTL type and aggregated years of exposure
to azoles were analysed. Aggregated years on azoles signifies the
number of years the patient had been on one or more azoles
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aggregatively before isolation of the strain. The years of concomitant
exposure to multiple azoles have been multiplied by the number of pre-
scribed azoles.
Northern blotting
Small-scale isolation of total RNA was performed from liquid cultures in
logarithmic growth phase as described earlier.26 Northern blotting was
performed to determine the mRNA expression for CDR1, CDR2, ERG11
and MDR1 as described previously.13 RNA samples were separated by
agarose gel electrophoresis and transferred to a nitrocellulose membrane
using the Vacuum Blotting System (Hoefer Scientific Instruments,
San Francisco, CA, USA). Probes were labelled with [a-32P]dATP with
random priming using the MegaPrime DNA Labeling System dNTP Kit
(GE Healthcare) according to the manufacturer’s instructions. Radioactive
signals were revealed by exposure to Kodak BioMax MR film (GE Health-
care). Signals obtained in blotted membranes were quantified by count-
ing radioactivity (Typhoon Trio; GE Healthcare). CDR1, CDR2, MDR, ERG11
and ACT1 probes were prepared by PCR using primers CYP-CB and CYP-
NS2, ACT-RT–PCR-F and -R. Primers used in this study are listed in
Table 1. As a control for the evaluation of expression levels of CDR1/2,
MDR1 and ERG11, the membranes were hybridized with ACT1 and the
amount of RNA was normalized according to the expression of ACT1.
The azole-susceptible strain isolated in 1995 from Patient 2 (fluconazole
MIC 1 mg/L) was chosen as a baseline control strain (0-level) and the
expression levels of the other isolates were quantified relative to the sus-
ceptible strain.
Immunoblotting
Western blotting was performed to evaluate Cdr1, Cdr2 and Mdr1 protein
expression. A C. albicans strain (DSY3849) known to overexpress Cdr1p
and Cdr2p was used as a positive control. A positive control for Mdr1p
was established by exposing the azole-susceptible strain isolated in
1995 from Patient 2 to benomyl for 30 min as described previously.29
Cell extracts were prepared as described by Sanglard et al.30 Ten microli-
tres of solubilized yeast protein was separated by 10% SDS/PAGE and
transferred by western blot onto a nitrocellulose membrane (Bio-Rad
Membrane). Immunodetection of Cdr1, Cdr2 and Mdr1 was performed
as described previously.19 A Super Signal West Pico Chemiluminescent
Kit (Thermo Scientific) and Amersham Hyperfilm (GE Healthcare) were
used according to the manufacturer’s instructions. The protein signals
visualized on the exposed films were interpreted as positive or negative.
Sequence analysis of ERG11 and TAC1
Genomic DNA for sequencing for TAC1 and ERG11 mutations was
extracted as described earlier.26 Sequences were amplified from
genomic DNAs by standard protocols as described previously for TAC131
Table 1. Primers used in this study
Primer Sequence
MLST
AAT1a-F 5′-CAGCAACATGATTAGCCC-3′
AAT1a-R 5′-ACTCAAGCTAGATTTTTGGC-3′
ACC1-F 5′-GCAAGAGAAATTTTAATTCAATG-3′
ACC1-R 5′-TTCATCAACATCATCCAAGTG-3′
ADP1-F 5′-GAGCCAAGTATGAATGATTTG-3′
ADP1-R 5′-TTGATCAACAAACCCGATAAT-3′
MPIb-F 5′-ACCAGAAATGGCCATTGC-3′
MPIb-R 5′-GCAGCCATGCATTCAATTAT-3′
SYA1-F 5′-AGAAGAATTGTTGCTGTTACTG-3′
SYA1-R 5′-GTTACCTTTACCACCAGCTTT-3′
VPS13-F 5′-TCGTTGAGAGATATTCGACTT-3′
VPS13-R 5′-ACGGATGGATCTCCAGTCC-3′
ZWF1b-F 5′-GTTTCATTTGATCCTGAAGC-3′
ZWF1b-R 5′-GCCATTGATAAGTACCTGGAT-3′
MTL status
MTLaplha 1-F 5′-TACATTCTGGTCGCGATGCTC-3′
MTLaplha 1-R 5′-GTAATCCAAAGCCTCGCATAA-3′
Northern blotting
CDR1-F 5′-AGTTGAGATCTACCCTTTAAGATATT-3′
CDR1-R 5′-TAATGACCAATTGAATCCCGATTCAG-3′
CDR2-F 5′-TGGTATATAAACTGGACAACATATCTG-3′
CDR2-R 5′-TAATGAACCAATTGAATCCCGATTCAG-3′
ERG11N 5′-CGGGATCCATGGGTGGTCAACATACTTCT-3′
ERG11C 5′-CGGAATTCCCTGCTGGTTCAGTAGGTAAAAC-3′
BENRN 5′-AAAAGCTTATGCATTACAGATTTTTAAGAG-3′
BENRC 5′-AAAAGCTTCTAATTAGCATACTTAGATCTT-3′
ACT1-RT-PCR-F 5′-GTTCCCAGGTATTGCTGAAC-3′
ACT1-RT-PCR-R 5′-CAATGGATGGACCAGATTCG-3′
TAC1 sequencing
Amplification
Zinc2-604 5′-ATAAGAGTGGCATGTGATA-3′
Zinc2-1123 5′’-GATGCCAACGAATTATTGA-3′
Zinc2-1708 5′-CAGAATTCGTTGGAGAATA-3′
Zinc2-2242 5′-GCCTTGTTACAATCAAGAA-3′
Zinc2-2683 5′-GCAGCATATCTTGTATTAG-3′
Zinc2-3224 5′-ATGCTCAGTCACCAAGTTA-3′
Zinc2-3087c 5′-GGTGTTCCTGCTACCACAA-3′
Zinc2-1789c 5′-ACATCAACAATGCCTTCTAC-3′
Zinc2-1247c 5′-TCTTCACCGTATGAACCTA-3′
Zinc2-778c 5′-CGTTGCTATTGGCGGTTGA-3′
Zinc2-1169 5′-TGTTGGTACTCATTCAATT-3′
Zinc2-1722 5′-TTGGAGAATAGTGCCATTT-3′
Zinc2-1510 5′-GCTACCAAGCGAAGGAGAT-3′
Zinc2-2465c 5′-TCTCTCGCCTAATTGACGT-3′
Sequencing
ZCF36SEQ1 5′-ATTACAATGTGTCCCACACAGG-3′
ZCF36SEQ2 5′-CAGTTTACTTTATCCATTTATGCC-3′
ERG11 sequencing
Amplification
ERG11-xho 5′-GCGCAACTCGAGCTCATATGAACAAGGTTGGGTAGTAA-3′
Continued
Table 1. Continued
Primer Sequence
ERG11-Kpn 5′-GAGCATGGGTACCGGCGCGCGATTGTACGT GG-3′
Sequencing
ERG11-3B 5′-CCCATTAAGAATCCCTGAA-3′
ERG11-5B 5′-CAGGGATTCTTAATGGGT-3′
ERG11-4 5′-CTGCTGGTTCAGTAGGTA-3′
ERG11-6 5′-GAGCAAATGAACGGTCAA-3′
MLST, multilocus sequence typing; MTL, mating-type locus.
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and ERG11.31 The sequences of primers used are listed in Table 1. The
alleles were sequenced using an AB3730XL DNA Analyzer (Applied Biosys-
tems). The resulting data were analysed using the Mutation Surveyor
software (Soft Genetics).
Statistical analysis
Data were analysed by using Graph Pad Prism version 5.00 (GraphPad
Inc., San Diego, CA, USA). Geometric means and range were used for
the analyses of MICs. The two-tailed Mann–Whitney t-test was used
for the comparisons of groups, and Spearman’s rho (rS) was used for
the analyses of correlations. Correlations are presented with a 95%
confidence interval and P value. P values of less than 0.05 were con-
sidered statistically significant.
Results
MLST typing
All seven patients with multiple C. albicans isolates analysed were
persistently colonized with the same strain for a mean of 5.0
years (range 1–9) (Table 2). Five of these seven patients (2, 4, 5, 6
and 7) had a pair of isolates identical by MLST. The mean time
Table 2. Characteristics of C. albicans isolates used in this study
Patient number/
year of isolation DST Clonal cluster
MIC (mg/L)
Time on
antifungal
(years)
MTL Genes overexpressed
Mutations detected by sequence
analysisa
FLC ITC FLC azolesb TAC1 ERG11
Patient 1
2001 1152 3 24 1 6 47 a/a CDR1, CDR2 F973S, S290C Y132F14
2004 1156 3 64 0.5 9 53 a/a CDR1, CDR2 F973S, S290C Y132F14
Patient 2
1995 360 4 1 0.094 1 12 a/a H283R
2001 360 4 64 12 7 41 a/a CDR1, CDR2 A736T31 H283R
Patient 3
2006 1157 1 48 1.5 6 36 a/a CDR1, CDR2 N740S
Patient 4
2001 1151 1 48 1 6 22 a/a CDR1, CDR2 N740S
2006 1493 1 6 1.5 7 23 a/a CDR1, CDR2 N977D31, P276L
2007 1493 1 32 4 7 24 a/a CDR1, CDR2 ND ND
Patient 5
1996 1489 S 8 0.75 2 13 a/a CDR1, CDR2 N972S31
2001 1489 S 48 12 2 20 a/a CDR1, CDR2 N972S31 G450E35, D153E36
2004 1318 S 32 1.5 2 29 a/a CDR1, CDR2 N972S31 G450E35, D153E36
Patient 6
2004 1494 11 128 2 3 28 a/a CDR1, CDR2 E461K31
2005 1494 11 32 1.5 3 28 a/a E461K31 S405F30
Patient 7
1995 1490 4 48 2 4 11 a/a CDR1, CDR2 R673Q31 V488I35
2001 1158 15 48 0.19 7 23 a/a S108N H283R
2004 1490 4 128 2 10 29 a/a CDR1, CDR2 R673Q31 V488I35
Patient 8
2004 1154 2 48 0.75 3 22 a/a CDR1 H741Y31
2006 1492 2 24 1.5 3 23 a/a H741Y31
Patient 9
2004 203 1 96 2 5 15 a/a CDR1, CDR2 N740D G464S14
MIC, minimum inhibitory concentration; DST, diploid sequence type; FLC, fluconazole; ITC, itraconazole; MTL, mating-type locus; ND, sequence not
determined; S, singleton.
aMutations A736T, N977D, N972S, E461K, R673Q and H741Y found in TAC1 alleles have previously been described as gain-of-function (GOF)
mutations. Mutations S108N, P276L, S290C, F973S, H283R, N740D and N740S (in bold) have not been previously described.
bAggregated years on azoles before isolation of the strain.
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elapsed between the isolation of these strains was 4.4 years (range
1–9). The isolates from the remaining two patients with multiple
isolates (Patients 1 and 8) differed in one or two genotypes and
were designated by different DST numbers but assigned to the
same clonal cluster. These differences mainly resulted from a loss
of heterozygosity at the sequenced loci. In one patient (Patient 7)
two strains belonging to different clonal clusters were identified.
Isolates from three patients (Patients 3, 4 and 9) belonged to
clonal cluster 1, and isolates from two patients (Patients 2 and 7)
belonged to clonal cluster 4. All other sets of isolates belonged to
different clonal clusters (2, 3 and 11). Isolates from Patient 5
were not assignable to a clonal cluster and were designated as sin-
gletons. The UPGMA dendrogram of the isolates is shown in
Figure 1. Isolates that belonged to clonal cluster 1 but were from
different patients did not co-cluster with very high levels of simi-
larity, whereas those that belonged to clonal cluster 4 formed a
more compact cluster. However, all patients were colonized with
different strains and no epidemic strains were found.
Susceptibility profiles of C. albicans isolates
The MIC of fluconazole for three isolates from three patients
(2/1995, 4/2006 and 5/1996) was ≤8 mg/L (Table 2). The
remaining 16 isolates had MICs ≥16 mg/L, of which five had MICs
≥64 mg/L. One patient (Patient 2) had one isolate (isolated in
1995) with an MIC of ≤0.125 mg/L of itraconazole and the fluco-
nazole MIC for this isolate was 1 mg/L. All other isolates had MICs
of ≥0.25 mg/L of itraconazole, and 14 of these isolates had MICs
of ≥1 mg/L. There was an increase in the fluconazole MICs for the
sets of isolates from four (Patients 2, 4, 5 and 7) of the remaining
five patients, with two isolates identical by MLST. An increase in
the itraconazole MICs was seen in the sets of isolates from
three (Patients 2, 4 and 5) of these five patients.
One patient set (Patient 1) showed an increase in the MIC of
fluconazole only. Four of the five identical DST pairs showed an
increase in fluconazole and itraconazole MICs. In all of these
cases systemic and/or topical azoles had been used between
the isolation of the strains (Table 2). A decrease in the MICs of
both azoles could be seen in one set (Patient 6) where azoles
had not been used between the isolation of the pair of strains.
In another patient set (Patient 8), where only miconazole had
been used between the isolation of the strains, a decrease in
the MIC of fluconazole but not itraconazole was seen. In
neither of these cases, however, did the MICs decrease signifi-
cantly or fall below the susceptible breakpoints according to
the CLSI standard.32
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Figure 1. Unweighted pair-group method with arithmetic mean (UPGMA) dendrogram of the isolates typed by multilocus sequence typing (MLST). The
scale bar shows genetic distance between the isolates. DST, diploid sequence type; S, singleton.
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MTL status
Of the 19 strains, 8 were found to be MTL homozygous (a/a or
a/a) and 11 were MTL heterozygous (a/a). The mean MICs for
the homozygous isolates (a/a or a/a) of fluconazole and itraco-
nazole were 45.4 (range 6–128) and 4.7 mg/L (range 0.5–12),
respectively. The mean MIC for the a/a type isolates (n¼4) was
35.1 mg/L (range 6–128) of fluconazole and 4.6 mg/L (range
2–12) of itraconazole. The mean MIC for the a/a type isolates
(n¼4) was 60.0 mg/L of fluconazole and 7.0 mg/L of itracona-
zole. The heterozygous (a/a) isolates had a mean MIC of 26.7
mg/L (range 1–128) of fluconazole and 1.4 mg/L (range
0.094–2) of itraconazole. The difference between the MICs for
homozygous and heterozygous isolates was statistically signifi-
cant for itraconazole (P¼0.0327) but not for fluconazole. In
the two isolate pairs with identical DSTs where loss of MTL het-
erozygosity could be observed (2/1995 and 2/2001; 5/1996
and 5/2001), the MICs of fluconazole increased. In one patient
(Patient 6), who had two strains with identical DSTs isolated
1 year apart, a decrease in the fluconazole MIC was seen conco-
mitantly with a shift from homozygosity to heterozygosity in MTL
status. MTL status did not correlate with years of exposure to
azoles. The correlation of MTL status with the aggregative
exposure to all azoles was also analysed since APECED patients
are often prescribed different azole antifungal agents and formu-
lations concomitantly (Table 2). The mean aggregated exposure
of the homozygous isolates (a/a and a/a) to azoles was
29.1 years and to fluconazole it was 5.3 years. For the heterozy-
gous isolates, the mean aggregated exposure to azoles was
24.2 years and to fluconazole it was 4.6 years.
CDR1/2, MDR1 and ERG11 mRNA expression
Fifteen (79%) of the 19 isolates showed overexpression of CDR1
and 14 (74%) showed overexpression of CDR2 by a mean of
9.8-fold (range3.5–19.4) and 20.4-fold (range 7.8–65.1), respect-
ively, when compared with the control isolate (Figure 2). Thirteen
(87%) of the isolates overexpressing CDR1 and 12 (86%) overex-
pressing CDR2 had fluconazole MICs ≥16 mg/L. Fourteen isolates
overexpressed both CDR1 and CDR2 and 12 (86%) of these had flu-
conazole MICs of ≥16 mg/L. All isolates overexpressing CDR1 or
CDR2 had itraconazole MICs ≥0.25 mg/L. In the four sets of iso-
lates identical by MLST with an increase in fluconazole MICs, the
relative expression level of CDR1 increased by a mean of 3.3-fold
(range 0.5–4.4) and that of CDR2 by a mean of 4.0-fold (range
0.5–11.2). The one pair of isolates identical by MLST (Patient 6),
where a decrease in the MIC of fluconazole was seen and the rela-
tive expression level of CDR1and CDR2decreased to the level of the
control isolate in 1 year, the patient had not been exposed to any
azoles between the isolation of the isolates.
Only two isolates (2006 isolate from Patient 3 and 2004 from
Patient 8) showed a slight (3.2- and 4.9-fold, respectively)
increase in the relative expression of MDR1 compared with the
control strain. The isolates had an MIC of 48 mg/L of fluconazole
and 0.75 and 1.5 mg/L of itraconazole. However, these isolates
also showed increased CDR1 mRNA levels. The expression of
ERG11 was low in our set of isolates (relative expression
ranging from 0.2 to 1.3). Fourteen isolates expressed ERG11 at
lower levels than the control, illustrating that azole resistance
does not necessarily arise from overexpression of ERG11.
Protein expression levels of Cdr1, Cdr2 and Mdr1
All isolates showing elevated Cdr1 and Cdr2 protein levels over-
expressed CDR1 and CDR2 mRNA. One isolate showed slightly
elevated CDR1 mRNA levels (3.9-fold when compared with the
control isolate) but no Cdr1 could be detected (Figure 2). Isolates
expressing Cdr1 also expressed Cdr2. Of the isolates that
expressed Cdr1 and Cdr2, the mean MIC of fluconazole was
44.5 mg/L and that of itraconazole was 1.8 mg/L, whereas the
isolates that did not express Cdr1p and Cdr2p had a mean MIC
of 6.9 mg/L of fluconazole and 0.3 mg/L of itraconazole. Mdr1p
expression was not detected.
TAC1 and ERG11 sequence analysis
TAC1mutations were detected in all but one isolate (isolate 1995
from patient 2) (Table 2). Twelve different mutations (A736T,
N977D, N972S, E461K, R673Q, H741Y, S108N, P276L, S290C,
F973S, N740S and N740D) were found in total. Six of these
mutations (S108N, P276L, S290C, F973S, N740S and N740D)
have not been described previously. Of these, all but P276L
were found in isolates with elevated azole MICs, and N740S
occurred in the absence of any other TAC1 or ERG11 mutations.
N740S was found in two unrelated strains isolated from different
patients. The mean relative expression level of CDR1 and CDR2 in
these two isolates was 11.1-fold (CDR1) and 14.6-fold (CDR2)
compared with the control isolate and their MIC of fluconazole
were 48 mg/L.
The sequence analysis of ERG11 revealed seven point
mutations (Y132F, H283R, G450E, D153E, S405F, V488I and
G464S) in 11 isolates. Two isolates (2001 and 2004) from
Patient 5 had two mutations (G450E and D153E). One mutation
(H283R) in ERG11 had not been previously reported. It was
detected in three isolates from two patients (Patients 2 and 7),
one of which was susceptible to azoles. In one pair of isolates
identical by MLST (Patient 6), acquisition of an S405F mutation
was observed in association with a decrease in azole MICs.
Pairs of isolates identical by MLST from three patients (Patients
1, 5 and 6) gained additional TAC1 or ERG11 mutations as well
as maintaining the pre-existing ones.
Discussion
Despite clinically successful antifungal treatment courses, the
APECED patients investigated here were found to be persistently
colonized with the same C. albicans strain over many years. All
patients were colonized with different strains and no epidemic
strains were found. Our findings are in accordance with those
of Li et al.,11 who found three HIV-infected patients to be persist-
ently colonized with closely related C. albicans strains despite
antifungal treatment. Microvariation was evidenced as small
differences between MLST types, resulting in most instances
from a loss of heterozygosity at one or more of the sequenced
loci. In the present study isolates from APECED patients exhibited
similar microvariation.
We have previously shown that the incidence of azole resist-
ance is high in C. albicans isolated from APECED patients.8 In
this study patients carrying C. albicans with decreased flucona-
zole susceptibility were included and multiple isolates with
various susceptibilities isolated over many years were analysed.
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Of the 19 isolates, 5 were found to be resistant, 11 were
susceptible-dose-dependent, and 3 were susceptible to flucona-
zole.32 Upregulation of CDR1 and CDR2 was significantly associ-
ated with the development of resistance. Fourteen (74%) of
the isolates showed increased expression of both genes and
one isolate only of CDR1. The Cdr1 and Cdr2 protein levels corre-
lated with the mRNA levels of CDR1 and CDR2. Upregulation of
CDR1 and CDR2 was reported to be the main molecular mechan-
ism of resistance in HIV patients with prolonged colonization by
C. albicans in a study by Perea et al.33 In their study, however, the
effect of exposure to antifungal agents was not analysed. We
have previously reported that the length of exposure to azoles
correlated with azole MICs in C. albicans isolated from APECED
patients.34 In the present study, six patients had been exposed
to azoles in the intervening years. The relative expression levels
of CDR1 and CDR2 in closely related pairs of isolates increased
on average by 2.1-fold (CDR1) and 2.7-fold (CDR2). The mean
aggregated exposure to azoles between these isolates was
8.0 years.
Several groups have reported a positive correlation between
loss of heterozygosity at the MTL locus and an increase in
azole MICs in C. albicans.14,20,21 In our set of isolates a similar
trend was observed, since the MIC of fluconazole increased in
both isolate pairs identical by MLST with a loss of heterozygosity
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Figure 2. RNA expression levels of CDR1, CDR2, MDR1, ERG11 and ACT1. (a) View of northern blot membranes and MICs (mg/L) of fluconazole. (b)
Relative expression of CDR1 and CDR2. (c) Relative expression of MDR1 and ERG11. Expression was quantified by comparison with ACT1 and then
relative expression levels of CDR1, CDR2, MDR1 and ERG11 were calculated for each isolate by comparison with the cognate levels of these genes
from the azole-susceptible isolate from Patient 2, isolated in 1995 (fluconazole MIC 1 mg/L). Dotted lines in (b) and (c) represent control isolate
1-fold expression levels for reference.
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at the MTL locus, i.e. there was a correlation between loss of het-
erozygosity and increased MICs for both fluconazole and itraco-
nazole. A change from homozygosity to heterozygosity at the
MTL locus was seen in one pair of MLST-identical strains
(Patient 6). It is possible that the patient was persistently colo-
nized with a number of closely related strains sharing a parent
strain that had undergone microvariation, and the chronology
of the isolation of the strains disagrees with the chronology of
genetic changes.
It has been demonstrated that GOF mutations in TAC1 are
associated with hyperactivity of the encoded protein, which is
itself responsible for enhanced transcription of TAC1 target
genes, including CDR1 and CDR2.19,35 In this study, TAC1mutations
were detected in all isolates with decreased susceptibility to azole
antifungals. Six new TAC1 mutations were found in addition to six
that had previously been described as GOF mutations.31 Of the
previously unidentified TAC1 mutations, N740S is a probable GOF
mutation since it is the only mutation present in two independent
isolates with raised azole MICs. The mutations S108N, S290C,
F973S and N740D are to be considered as potential GOF
mutations but their role remains unclear because they were
detected in isolates that contained other mutations. Six previously
described ERG11 mutations contributing to azole resistance were
also identified.14,16,36–38 In addition, a previously unidentified
mutation (H283R) was detected in ERG11, but it was found in
both azole-resistant and azole-susceptible isolates and is there-
fore unlikely to be a GOF mutation.
Point mutations in TAC1 and ERG11 seemed to remain stable
during the period (years) between isolates. Isolates (2001 and
2004) from Patient 5 had acquired two point mutations in
ERG11 after the isolation of the 1996 strain. The mutations
were accompanied by loss of heterozygosity at the MTL locus,
which was also likely to contribute to the increase in the MICs
in the presence of a rather surprising 2.2-fold decrease in the
expression of both CDR1 and CDR2. However, both CDR1 and
CDR2 were upregulated in all isolates relative to the susceptible
control strain. The TAC1 mutation remained identical in all
these isolates. The patient had not been exposed to fluconazole
during the intervening years but had been administered other
azoles. Patient 2 had gained a GOF mutation in TAC1. This
patient had been exposed to fluconazole for 6 years between
the isolation timepoints and the MIC of fluconazole had
increased from 1 to 64 mg/L. The DST had remained the same.
In one pair of isolates identical by MLST (Patient 6), acquisition
of a point mutation in ERG11 (S405F) was detected in association
with minor increases in relative ERG11 and MDR1 expression and
decreases in CDR1 and CDR2 expression, resulting in a decrease in
azole MICs. In another pair of isolates identical by MLST (1995
and 2004, Patient 7) with identical TAC1 and ERG11 mutations
and the same MTL status, the fluconazole MIC increased (from
48 to 128 mg/L) in association with a 4.3-fold increase in CDR1
and 1.5-fold increase in CDR2 expression levels.
In conclusion, our results confirm that APECED patients
become persistently colonized with unique C. albicans strains
undergoing microvariation over time. Clinically successful treat-
ment has not led to eradication of the colonizing Candida popu-
lation and re-infection with another strain. The major molecular
mechanisms mediating azole resistance were GOF mutation in
TAC1, contributing to overexpression of CDR1 and CDR2, and
point mutations in ERG11. Six new TAC1 mutations were
detected, one of which (N740S) is likely to be a GOF mutation.
Most isolates were found to have gained multiple TAC1 and
ERG11 point mutations. However, the role of individual mutations
in azole resistance in C. albicans needs further analysis.
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